Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

Summary

The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.

Timeline

Start

2013-09

Primary completion

2018-05

Completion

2019-08

Publications

• Graham DY, Naser SA, Borody T, Hebzda Z, Sarles H, Levenson S, Hardi R, Arlukowicz T, Svorcan P, Fathi R, Bibliowicz A, Anderson P, McLean P, Fehrmann C, Harris MS, Zhao S, Kalfus IN. Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn's Disease. Antibiotics (Basel). 2024 Jul 25;13(8):694. doi: 10.3390/antibiotics13080694.

Drugs

Indications